Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Otsuka Holds Talks With Korean Government On R&D Project

This article was originally published in PharmAsia News

Executive Summary

SEOUL - The Korean unit of Japan's Otsuka Pharmaceuticals is holding negotiations with South Korea's Ministry for Heath, Welfare and Family Affairs on investing in drug research and development, and the two sides could soon sign a memorandum of understanding, according to a Korea Otsuka executive

You may also be interested in...



Japan's Otsuka Signs MOU To Invest $83 Million In Korea By 2013

SEOUL - Japan's Otsuka Pharmaceuticals signed a memorandum of understanding with Korea's health ministry to invest roughly KRW100 billion ($83 million) in research and development of new drugs as well as for clinical trials over the next five years in Korea

Japan's Otsuka Signs MOU To Invest $83 Million In Korea By 2013

SEOUL - Japan's Otsuka Pharmaceuticals signed a memorandum of understanding with Korea's health ministry to invest roughly KRW100 billion ($83 million) in research and development of new drugs as well as for clinical trials over the next five years in Korea

Multinationals Step Up Clinical Trials In South Korea

SEOUL - More and more multinational companies are coming to South Korea to conduct clinical trials, taking advantage of the country's well-trained workforce, well-established infrastructure, lower cost compared with other advanced countries and competitive R&D capability

Related Content

UsernamePublicRestriction

Register

SC071851

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel